Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
Received 7 September 2019
Accepted for publication 17 December 2019
Published 6 January 2020 Volume 2020:14 Pages 33—43
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Jens Vent-Schmidt,1,2,* Gail P Attara,3,* Daniel Lisko,1 Theodore S Steiner1
1Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; 2Department of Biology, Kwantlen Polytechnic University, Langley, BC V3A 8G9, Canada; 3Gastrointestinal Society, Canadian Society of Intestinal Research, Vancouver, BC V5R 5W2, Canada
*These authors contributed equally to this work
Correspondence: Theodore S Steiner
Department of Medicine, University of British Columbia, 950 West 28 th Ave, Vancouver, BC V5Z 4H4, Canada
Tel +1 604 845 2000 ext. 4910
Purpose: Clostridioides difficile infection (CDI) is the most prevalent cause of nosocomial infectious diarrhea in Canada and is highly correlated with antibiotic use and contact with health care facilitates. The often-severe symptoms of CDI include diarrhea, dehydration, and abdominal pain. Patients often relapse following symptom resolution, resulting in increased morbidity. Previous research on the impact of CDI centered around the health-care system, clinician perspectives and economic burden, but not on patient experiences. The purpose of this study was to understand the impact of CDI on patients in Canada.
Methods: The Gastrointestinal Society conducted online surveys and gathered data from 167 qualifying participants, who were either patients or their non-treating caregivers. Quantitative parameters were analyzed by descriptive and comparative statistics and contextualized with qualitative insights derived from thematic analysis of open-ended questions.
Results: Our findings, which focused on clinical parameters such as prior exposure to health-care settings, antibiotic use, and patients’ symptoms, mirrored findings from previous research. Interestingly, most surveyed respondents experienced delays in diagnosis and treatment; 29% waited 6–30 days and 10% over 30 days. This delayed diagnosis was further complicated by the report that 62% of respondents did not experience symptom resolution within 7 days of initiating treatment. Importantly, our results suggest a lasting impact after the resolution of CDI and we saw a reduction of self-assessed quality of life from prior to post CDI. Patients’ priorities regarding their experience with CDI focused around concerns about the health-care system, particularly time to diagnosis and treatment, concerns about antibiotic usage and needs from health-care providers.
Conclusion: This is the first Canadian report on patients’ experience with CDI. Our data highlight the symptom-related impact on patients and the long-lasting effect on the quality of life including emotional impact. Reducing time to diagnosis and improving patient education are important priorities to attenuate the impact on patients.
Keywords: nosocomial infection, Clostridium difficile colitis, C difficile, CDI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]